Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — April 2024

Biotek-snakken — April 2024

Planlagt Fastgjort Låst Flyttet Biotek-snakken
112 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • F Offline
    F Offline
    Fandel
    wrote on sidst redigeret af
    #45

    Godmorgen...

    1 Reply Last reply
    0
    • Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktør
      wrote on sidst redigeret af
      #46

      Alvotech And Teva : FDA Approves Selarsdi Injection For Psoriasis And Psoriatic Arthritis https://www.proinvestor.com/investornyt/1145923/alvotech-and-teva-fda-approves-selarsdi-injection-for-psoriasis-and-psoriatic-arthritis

      1 Reply Last reply
      0
      • L Offline
        L Offline
        LP90
        wrote on sidst redigeret af
        #47

        Godmorgen 🙂

        1 Reply Last reply
        0
        • P Offline
          P Offline
          ProinvestorNEWS
          wrote on sidst redigeret af
          #48

          ULTIMOVACS: Biotekselskapet melder at de vil redusere antall ansatte med 40% slik at de skal ha likviditet til å nå ytterligere to datapunkter - pengene skal etter plan holde til Q4 2025.

          1 Reply Last reply
          0
          • F Offline
            F Offline
            Fandel
            wrote on sidst redigeret af
            #49

            Godmorgen...

            1 Reply Last reply
            0
            • L Offline
              L Offline
              LP90
              wrote on sidst redigeret af
              #50

              Godmorgen 🙂

              1 Reply Last reply
              0
              • exitnuE Offline
                exitnuE Offline
                exitnu
                wrote on sidst redigeret af
                #51

                Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

                Link Preview Image
                Calliditas Therapeutics AB

                Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

                favicon

                Calliditas Therapeutics AB (www.calliditas.se)

                1 Reply Last reply
                0
                • F Offline
                  F Offline
                  Fandel
                  wrote on sidst redigeret af
                  #52

                  Godmorgen...

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    LP90
                    wrote on sidst redigeret af
                    #53

                    Godmorgen 🙂

                    1 Reply Last reply
                    0
                    • F Offline
                      F Offline
                      Fandel
                      wrote on sidst redigeret af
                      #54

                      Godmorgen...

                      1 Reply Last reply
                      0
                      • F Offline
                        F Offline
                        Fandel
                        wrote on sidst redigeret af
                        #55

                        Godmorgen...

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #56

                          BioArctic And Eisai Collaborate On Evaluating BAN2802 For Alzheimer's Disease https://www.proinvestor.com/investornyt/1148131/bioarctic-and-eisai-collaborate-on-evaluating-ban2802-for-alzheimers-disease

                          1 Reply Last reply
                          0
                          • H Offline
                            H Offline
                            Hansen
                            wrote on sidst redigeret af
                            #57

                            Xbane lidt nyt https://xbrane.com/mfn_news/xbrane-uppdaterar-kring-fdas-granskning-av-ranibizumab-biosimilarkandidat/

                            1 Reply Last reply
                            0
                            • H Offline
                              H Offline
                              Hansen
                              wrote on sidst redigeret af
                              #58

                              Xbrane 🙂

                              1 Reply Last reply
                              0
                              • F Offline
                                F Offline
                                Fandel
                                wrote on sidst redigeret af
                                #59

                                Godmorgen...

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  LP90
                                  wrote on sidst redigeret af
                                  #60

                                  Godmorgen 🙂

                                  1 Reply Last reply
                                  0
                                  • exitnuE Offline
                                    exitnuE Offline
                                    exitnu
                                    wrote on sidst redigeret af
                                    #61

                                    God morgen 🙂

                                    1 Reply Last reply
                                    0
                                    • exitnuE Offline
                                      exitnuE Offline
                                      exitnu
                                      wrote on sidst redigeret af
                                      #62

                                      En fabriksorienteret Complete Response Letter (CRL) kan typisk resultere i en forlængelse på 1 til 6 måneder, men i visse tilfælde kan forlængelsen vare op til 12 måneder eller mere.

                                      "Receiving a complete response letter is not a rejection, but it introduces important business questions for product launch planning."

                                      https://avalere.com/insights/what-is-a-complete-response-letter

                                      (Avalere)

                                      1 Reply Last reply
                                      0
                                      • H Offline
                                        H Offline
                                        Hansen
                                        wrote on sidst redigeret af
                                        #63

                                        På den positive side, lyder det som om at det er overkommeligt at efterkomme. Ikke mindst at der ikke kræves flere forsøg. Eller er det for optimistisk at se på det sådan?

                                        1 Reply Last reply
                                        0
                                        • exitnuE Offline
                                          exitnuE Offline
                                          exitnu
                                          wrote on sidst redigeret af
                                          #64

                                          Complete Response Letter (CRL) betyder en udfordring for Xbrane. De skal håndtere forsinkelsen, ekstra omkostninger men også en ekstra usikkerhed omkring godkendelse. Rent statistisk er høj godkendelsesraten for biosimilar ganske pæn. Har ikke Xbrane.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper